Skip to content

Robert Madejek

2 papers in the library · 4 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Early Outcomes from Poland’s First Psychiatric Drug Program B.147

European Psychiatry June 1, 2026 O. Płaza, R. Madejek, M. M. Dutsch-Wicherek et al.

Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...